ELAN Q1 2020 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena

ELANElanco Animal Health Incorporated

$12B

Q1 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$658M-10.0% YoY

Gross Profit

$273M41.6% margin

Operating Income

$25M3.7% margin

Net Income

-$49M-7.5% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

-16.4%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

-$40M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$9.7B

Total Liabilities

$3.1B

Stockholders' Equity

$6.7B

Cash & Equivalents

$1.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$658M	$731M	-10.0%
Gross Profit	$273M	$338M	-19.2%
Operating Income	$25M	$93M	-73.6%
Net Income	-$49M	$32M	-255.9%

Revenue Segments

Food Animal Ruminants And Swine

$253M38%

Food Animal Future Protein And Health

$180M27%

Companion Animal Disease Prevention

$140M21%

Companion Animal Therapeutics

$66M10%

Strategic Exits

$19M3%

Geographic Segments

Non-US

$358M54%

UNITED STATES

$300M46%